Page 36 - TD-4-3

Tumor Discovery Immunomodulatory effects of CDK4/6 inhibitors

Radiat Oncol Biol Phys. 2024;120(2 Suppl):S46. 43. Liu C, Huang Y, Cui Y, et al. The immunological role of
CDK4/6 and potential mechanism exploration in ovarian
doi: 10.1016/j.ijrobp.2024.07.071
cancer. Front Immunol. 2021;12:799171.
33. Zhang QF, Li J, Jiang K, et al. CDK4/6 inhibition promotes doi: 10.3389/fimmu.2021.799171
immune infiltration in ovarian cancer and synergizes with
PD-1 blockade in a B cell-dependent manner. Theranostics. 44. Lee DH, Imran M, Choi JH, et al. CDK4/6 inhibitors
2020;10(23):10619-10633. induce breast cancer senescence with enhanced anti-tumor
immunogenic properties compared with DNA-damaging
doi: 10.7150/thno.44871
agents. Mol Oncol. 2024;18(1):216-232.
34. Heckler M, Ali LR, Clancy-Thompson E, et al. Inhibition of doi: 10.1002/1878-0261.13541
CDK4/6 promotes CD8 T-cell memory formation. Cancer
Discov. 2021;11(10):2564-2581. 45. Pandey P, Khan F, Upadhyay TK, Sharangi AB. Deciphering
the immunomodulatory role of cyclin-dependent kinase 4/6
doi: 10.1158/2159-8290.CD-20-1540 inhibitors in the tumor microenvironment. Int J Mol Sci.
35. Teh JLF, Erkes DA, Cheng PF, et al. Activation of CD8 T cells 2023;24(3):2236.
+
contributes to antitumor effects of CDK4/6 inhibitors plus doi: 10.3390/ijms24032236
MEK inhibitors. Cancer Immunol Res. 2020;8(9):1114-1121.
46. Watt AC, Cejas P, DeCristo MJ, et al. CDK4/6 inhibition
doi: 10.1158/2326-6066.CIR-19-0743 reprograms the breast cancer enhancer landscape by
36. Bai X, Guo ZQ, Zhang YP, et al. CDK4/6 inhibition triggers stimulating AP-1 transcriptional activity. Nat Cancer.
ICAM1-driven immune response and sensitizes LKB1 2021;2(1):34-48.
mutant lung cancer to immunotherapy. Nature Commun. doi: 10.1038/s43018-020-00135-y
2023;14(1):1247.
47. Fan H, Liu W, Zeng Y, et al. DNA damage induced by
doi: 10.1038/s41467-023-36892-4 CDK4 and CDK6 blockade triggers anti-tumor immune
37. Ruscetti M, Leibold J, Bott MJ, et al. NK cell-mediated responses through cGAS-STING pathway. Commun Biol.
cytotoxicity contributes to tumor control by a cytostatic 2023;6(1):1041.
drug combination. Science. 2018;362(6421):1416-1422. doi: 10.1038/s42003-023-05412-x
doi: 10.1126/science.aas9090 48. Charles A, Bourne CM, Korontsvit T, et al. Low-dose
38. Wu Y, Shrestha P, Heape NM, Yarchoan R. CDK4/6 CDK4/6 inhibitors induce presentation of pathway specific
inhibitors sensitize gammaherpesvirus-infected tumor cells MHC ligands as potential targets for cancer immunotherapy.
to T-cell killing by enhancing expression of immune surface Oncoimmunology. 2021;10(1):1916243.
molecules. J Transl Med. 2022;20(1):217. doi: 10.1080/2162402X.2021.1916243
doi: 10.1186/s12967-022-03400-z 49. Liu J, Cheng M, Xu J, Liang Y, Yin B, Liang J. Effect of
39. Lai AY, Sorrentino JA, Dragnev KH, et al. CDK4/6 inhibition CDK4/6 inhibitors on tumor immune microenvironment.
enhances antitumor efficacy of chemotherapy and immune Immunol Invest. 2024;53(3):437-449.
checkpoint inhibitor combinations in preclinical models and doi: 10.1080/08820139.2024.2304565
enhances T-cell activation in patients with SCLC receiving 50. Stopfer LE, Mesfin JM, Joughin BA, Lauffenburger DA,
chemotherapy. J Immunother Cancer. 2020;8(2):e000847.
White FM. Multiplexed relative and absolute quantitative
doi: 10.1136/jitc-2020-000847 immunopeptidomics reveals MHC I repertoire
40. Salewski I, Henne J, Engster L, et al. CDK4/6 blockade alterations induced by CDK4/6 inhibition. Nat Commun.
provides an alternative approach for treatment of 2020;11(1):2760.
mismatch-repair deficient tumors. Oncoimmunology. doi: 10.1038/s41467-020-16588-9
2022;11(1):2094583.
51. Kumar A, Ramani V, Bharti V, et al. Dendritic cell therapy
doi: 10.1080/2162402X.2022.2094583 augments antitumor immunity triggered by CDK4/6
inhibition and immune checkpoint blockade by unleashing
41. Sun M, Dong L, Wang Y, et al. The role of targeting CDK4/6 systemic CD4 T-cell responses. J Immunother Cancer.
in cancer immunotherapy. Holist Integr Oncol. 2024;3(1):32.
2023;11(5):e006019.
doi: 10.1007/s44178-024-00100-0
doi: 10.1136/jitc-2022-006019
42. Zhang S, Xu Q, Sun W, Zhou J, Zhou J. Immunomodulatory
effects of CDK4/6 inhibitors. Biochim Biophys Acta Rev 52. Kohlmeyer JL, Lingo JJ, Kaemmer CA, et al. CDK4/6-
MEK inhibition in MPNSTs causes plasma cell infiltration,
Cancer. 2023;1878(4):188912.
sensitization to PD-L1 blockade, and tumor regression. Clin
doi: 10.1016/j.bbcan.2023.188912 Cancer Res. 2023;29(17):3484-3497.

Volume 4 Issue 3 (2025) 28 doi: 10.36922/TD025190037